Contrast agent developer Epix Medical of Cambridge, MA, and Schering of Berlin have signed a partnership agreement to fund research and development of MRI contrast agents, as well as a blood clot detection product, EP-2104R.
For EP-2104R, Epix will conduct early development activities, which Schering will support with up to $9 million. For the exclusive research partnership on MRI contrast agents, Schering committed funding of approximately $4 million over the next two years, and a loan facility of up to $15 million, with principal repayment beginning in 2007, according to Epix.
By AuntMinnie.com staff writersMay 27, 2003
Related Reading
Epix revenues gain, losses widen, April 25, 2003
Epix to develop new MR agent, April 1, 2003
Epix contrast agent clears second phase III trial, March 8, 2003
Epix testing of MS-325 moves forward, February 4, 2003
Epix losses continue, MS-325 enrollment completed, October 25, 2002
Copyright © 2003 AuntMinnie.com
